|
Stock Hunter Presents!! WZE,ACLS,ALTR,ALVR,ALXA,ARGN:: Sign Up Today!!
(M2 PressWIRE Via Acquire Media NewsEdge) Stock Hunter PRESENTS : (NYSE: WZE) Wizzard Software Corp., (NASDAQ: ACLS) Axcelis Technologies, Inc., (NASDAQ: ALTR) Altera Corp., (NASDAQ: ALVR) Alvarion Ltd., (NASDAQ: ALXA) Alexza Pharmaceuticals, Inc., (NASDAQ: ARGN) Amerigon Inc.
www.Stockhunter.us
To sign up for our free Profiles & Alerts :: visit http://www.StockHunter.us
email us!! info@StockHunter.us
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NYSE: WZE - Wizzard Software Corp.)
LATEST NEWS!!
Wizzard Media Launches First of Its Kind Reoccurring Revenue Model for Podcast Publishers Through In App Purchasing for iPhone Apps
The Monetization Revolution For Mobile Media Has Begun
PITTSBURGH, Feb 10, 2010 -- Wizzard Media (NYSE Amex: WZE), the world's largest podcasting network, today announced the availability of In App Purchasing for its Podcast App in the iTunes App store. The updated App was recently approved by Apple and is available for Wizzard's podcast companion App publishers immediately.
With an average podcast App sale price of $1.99, Wizzard's top App publishers have converted approximately 24% of their audience from free, to paid users. Now, with In App Purchasing capabilities, podcast publishers can offer their paid audience additional features and content, charging a one-time fee or a reoccurring subscription price. This new feature can substantially increase the amount of revenue generated per audience member. With the audience conversion rates currently being achieved, the Company believes it can substantially increase its per audience member revenue with this new monetization feature.
Wizzard recently announced 2009 network numbers of over 12,000 podcasts downloaded 1.4 billion times by over 18 million unique monthly audience members, approximately 50 million unique annual audience members. Until recently, Wizzard's only means to derive revenues was through podcast publishing services as well as advertising sales.
With the launch of the iPhone App store in iTunes(R), Wizzard created a unique iPhone App that can be quickly customized for each podcast and allows podcast publishers to generate a new, multi-faceted revenue stream by marketing their own iPhone App directly to their audience. Wizzard shares in this revenue with the podcast publisher. Wizzard believes that unlike most of the 140,000 Apps in the App Store, podcasters have a distinct advantage in successfully marketing their App due to the fact that they have already built a substantial audience for their podcast show through iTunes.
"Now, podcasting becomes a platform that converts audiences to revenue, accelerated by the micropayment billing process that Apple has created with the App store. We believe this new process is the future model for how digital media will be published, audiences grown and revenues derived," says Chris Spencer, Wizzard Media CEO. "Never before has there been a monetization method like this for podcast producers because the technology to simplistically charge for content was not available. After assembling a massive network of podcasts over the last three years, Wizzard believes its podcast App is the much anticipated positive catalyst for both revenue acceleration as well as its position in the surging mobile media landscape rapidly taking shape." Wizzard Media generates revenues three ways: 1) charging for publishing services such as podcast hosting, distribution and audience statistics; 2) podcast advertising sales; 3) podcast App, content sales and subscriptions. As recently as last week the Company added advertising capabilities to its podcast App to compliment its current in-content advertising products. Today they are adding the ability to sell podcast episodes and subscriptions for premium content directly through their podcast App via iTunes.
"We know there is strong demand for the podcasts we distribute seeing downloads grow from 400 million to 1.4 billion in the last three years and monthly audiences grow from 4 million to over 18 million," says Laurie Sims, President of Wizzard Media.
"While In App Purchasing won't necessarily work for all Apps, we believe it has huge potential for the rich, episodic content of our podcast Apps," says Dave Mansueto, co-founder Wizzard Media. "It gives our podcasters the opportunity to offer their audience inexpensive subscription packages for new and exclusive content. With over 12,000 content creators and tens of thousands of new episodes being added to the Wizzard Network quarterly, we believe we have a model here that can be recreated over and over. This is a new opportunity for our producers to extend the reach of their content and make money doing so." Analysts project the App market to be a $1.0 billion market today, headed for $4.0 billion by 2012. Having witnessed significant growth during the most recent holiday season and the recent launch of the iPhone in China, Wizzard believes the number of people using iPhones, iPads and iPod Touches to consume podcasts and interact with Apps will continue to grow well beyond the current 70 million user-base.
Click here to learn more about Wizzard's podcast App for the iPhone Click here to learn more about Apple's In App Purchasing technology About Wizzard Media: Wizzard Media provides podcast publishers with distribution and monetization services. Our clients include Microsoft, National Geographic, Harvard Business Review, Usher, NPR and more than 12,000 others who use Wizzard Media products to measure their podcast audience, deliver popular audio and video entertainment and monetize their content through advertising and App sales. In 2009, the Wizzard Media Network received over 1.4 billion podcast requests from approximately 50 million people worldwide through iPods, iPhones, iTunes, Zune and many other devices and destinations. We are part of a publicly held, Pittsburgh based company with thousands of shareholders and a world-class team. Visit us on the web at www.wizzardsoftware.com/media, email us at contact@wizzard.tv.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: ACLS - Axcelis Technologies, Inc.)
LATEST NEWS!!
Axcelis Expands Reach of Optima HDx High Current Implanter With New Design Win for Multiple Fab Presence
System Selected for High Productivity and Capital Efficiency
BEVERLY, Mass., Feb 10, 2010 -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of innovative, high-productivity solutions for the semiconductor industry, announced today that it has received an order for the company's Optima HDx high current implanter from a leading chip manufacturer that extends the use of this technology across multiple fabs. The customer currently utilizes the Optima HDx for high volume manufacturing, and will now expand the deployment of the system to its newest fab.
Mary Puma, chairman and CEO commented, "We're very excited about this order, as it validates the attractiveness of the tool across multiple fab environments. This new win is part of a recent trend of orders for the Optima HDx, and demonstrates the growing acceptance and demand for our high current technology. We look forward to continuing to expand our installed base with this industry leader and supporting their evolving manufacturing and next generation development needs." An extension of the company's Optima HD platform, the Optima HDx has been designed to provide chipmakers dramatically increased productivity and capital efficiency. The Optima HDx features a unique combination of enhancements to maximize beam current, minimize beam set up time and eradicate energy contamination to deliver the most precise and repeatable performance in the high dose space. The system's unique spot beam technology and short beamline deliver the industry's highest drift beam currents, 38% higher than its competitors. To further enhance performance, its patented AutoTune beam tuning system has significantly accelerated both tune times and success rates, providing up to a 60% advantage over competitive systems, for increased fab productivity.
Axcelis Technologies, Inc. (Nasdaq:ACLS) headquartered in Beverly, Massachusetts, provides innovative, high-productivity solutions for the semiconductor industry. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation and cleaning systems. The company's Internet address is: www.axcelis.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: ALTR - Altera Corp.)
LATEST NEWS!!
Altera's Stratix IV FPGAs Continue to Receive Accolades from Worldwide Editorial Community
SAN JOSE, Calif., Feb 10, 2010 -- Altera Corporation (NASDAQ: ALTR) today announced its 40-nm Stratix(R) IV FPGA family was presented with several new awards from the electronics editorial community. Editors from Application of Electronics Technique (AET), China Electronics News (CEN) and VME and Critical Systems Magazine recognized the Stratix IV family for a number of innovations, including its density, performance and power advantage, and its leadership position in leading-edge process technology. Since devices started shipping in December 2008, ten electronics trade publications have presented Stratix IV FPGAs with 12 product and technology awards. The latest recognitions include: -- Stratix IV GX FPGAs were awarded with AET's Best Programmable Logic Device Award and were included in the magazine's 2009 Leading Electronic Products issue. AET readers and industry experts recognized Stratix IV GX FPGAs for the devices' achievements in performance, power, innovation and wide market application.
-- Altera was presented with CEN's Leading FPGA Technology Award as part of its 2009 Editor's Choice Award selection. The magazine's editors recognized Altera for its breakthroughs in delivering the industry's first 40-nm FPGA in volume production in 2009, as well as the innovations Altera made to Cyclone(R) FPGAs and Quartus(R) II software.
-- Stratix IV FPGAs received VME and Critical Systems Magazine's Editor's Choice Award. The publication's editors recognized Altera's high-density Stratix IV EP4SE820 FPGA for its technology leadership. The FPGA features 820K logic elements (LEs) and offers the highest performance and lowest power in its class.
"Altera achieved great technology breakthroughs in 2009 by delivering production silicon based on leading-edge process technology with its Stratix IV FPGAs," said Zhao Yanqiu, editor-in-chief, basic electronics of CEN. "The company further demonstrated its technology leadership by expanding its proven Cyclone series FPGAs and delivering new features and enhancements to its Quartus II software. With all these achievements, Altera is well deserving of this award." "Stratix IV FPGAs deliver technology leadership on many levels, including density, performance, power and system bandwidth," said Luanne Schirrmeister, senior director of component product marketing at Altera. "We are honored and grateful that the editors of these prestigious trade magazines recognize the innovations within Stratix IV FPGAs and the significance of these devices to the electronics community." Availability All three variants of the Stratix IV FPGA family are in production and available today. To learn more about Altera's high-performance FPGA family, contact your local Altera sales representative or visit www.altera.com/stratix4.
About Altera Altera programmable solutions enable system and semiconductor companies to rapidly and cost-effectively innovate, differentiate and win in their markets. Find out more about Altera's FPGA, CPLD and ASIC devices at www.altera.com
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: ALVR - Alvarion Ltd.)
LATEST NEWS!!
Alvarion(R) Demonstrates WiMAX(TM) Market Leadership by Showcasing 4G Solutions and End User Devices at Mobile World Congress 2010
Company to feature its portfolio of 4G WiMAX end user devices derived from an extensive, mature ecosystem
TEL-AVIV, Israel, Feb 10, 2010 -- During Mobile World Congress, Alvarion Ltd. (NASDAQ: ALVR) announced it will showcase a broad range of 4G WiMAX end user devices, end-to-end network solutions and innovative wireless applications, highlighting the collaboration with open network of partners.
As the world's leading provider of 4G WiMAX solutions with more than 3.5 million wireless devices deployed around the globe, Alvarion offers a complete portfolio of field-proven WiMAX devices -- ranging from indoor and outdoor CPEs, USB dongles and embedded laptops and netbooks. Alvarion's OPEN WiMAX device strategy is aimed at bringing advanced ecosystem devices to the market with Alvarion branded devices as well as third party devices through its partner interoperability testing (IOT) program. The key elements of our approach includes a comprehensive choice of different types of devices, IOT with multiple WiMAX chipset vendors and a streamlined device IOT program for a faster time to market. Alvarion's offering is based on superior technology innovations, a broad ecosystem and unparalleled deployment experience, enabling its customers to adopt unique business cases.
The following activities are planned at Alvarion's booth in Hall 2 (#C25): Display of end user devices -- Alvarion's booth will showcase over 20 end user devices, including embedded WiMAX laptops, netbooks, a variety of USB dongles, MIDs, UMPCs and Mobile Hot Spots.
Demos -- Alvarion's booth will also demonstrate state of the art WiMAX base stations connected live with several WiMAX devices.
Speaking program -- Alvarion will also host daily sessions from its ecosystem partners in the booth on various topics. Some specific topics that will be covered are: -- Taiwan WiMAX ecosystem -- Value added services platform -- Optimization of wireless networks in the age of rich video consumption -- The role of automatic video production over 4G networks -- VoIP and mobile services for WiMAX providers -- Cross network and device media delivery platform -- Wireless backhaul "Alvarion is proud to be leading the world of 4G today with our Open WiMAX solutions," said Mohammad Shakouri, Corporate VP Innovation and Marketing of Alvarion. "We look forward to showcasing extensive array of end user devices, along with innovative applications supplied by our partners as further evidence that our Open WiMAX strategy is progressing and WiMAX technology and devices are bringing benefits of wireless broadband to end-users around the globe." About Alvarion Alvarion (NASDAQ:ALVR) is a global leader in 4G wireless communications with the industry's most extensive customer base with hundreds of commercial WiMAX deployments. Alvarion's industry leading solutions enable true open 4G and vertical applications for service providers and enterprises. Through an OPEN WiMAX strategy, superior IP and OFDMA know-how, and ability to deploy large scale end-to-end turnkey networks, Alvarion is delivering the true 4G broadband experience today (www.alvarion.com)
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: ALXA - Alexza Pharmaceuticals, Inc.)
LATEST NEWS!!
Alexza and Biovail Form Collaboration to Develop and Commercialize AZ-004 (Staccato(R) Loxapine) in North America
Conference Call Scheduled for Today -Wednesday, February 10, 2010 at 8:30 a.m. Eastern Time
MOUNTAIN VIEW, Calif., Feb 10, 2010 -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to develop and commercialize AZ-004 (Staccato(R) loxapine) in the U.S. and Canada. AZ-004 is Alexza's lead program, based on the company's proprietary technology, the Staccato system. Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. Alexza is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder.
"We are very excited to be partnering our lead program with Biovail. Their key strategic focus and their CNS commercial plans match our view of an ideal partner for AZ-004," said Thomas B. King, Alexza President and CEO. "We believe that AZ-004, if approved, has the potential to change the treatment practices for acute agitation, as the only product able to meet both the patients' desire for quickly and comfortably gaining control of their agitation, and the clinicians' goal of rapidly and reliably calming an agitated patient.
"This agreement provides Biovail with a promising late-stage specialty CNS product," said Bill Wells, Biovail's Chief Executive Officer. "In clinical studies conducted by Alexza, Staccato loxapine rapidly delivered drug into the blood stream through the deep lung in a unique, non-invasive manner. We are delighted to be partnering with Alexza to bring this important treatment to market." The collaboration provides for the development and commercialization of AZ-004 for multiple indications, including the proposed initial indication of treating agitation in schizophrenia and bipolar patients, as well as potential future clinical development in additional psychiatric and neurological indications and the symptoms associated with these indications. Biovail will lead the commercialization activities for AZ-004. Alexza will continue to manage the ongoing AZ-004 NDA review and approval process in connection with the initial indication, and has entered into a manufacturing and supply agreement to supply Biovail clinical and commercial product.
Under the terms of the collaboration, Alexza is entitled to receive an upfront cash payment of $40 million, up to $90 million in potential milestone payments contingent on the successful approval of the first AZ-004 NDA, successful commercial manufacturing scale-up, and the successful completion of additional clinical trials, regulatory submission (if required) and approval of an sNDA (if required) in the outpatient setting for patients with schizophrenia or bipolar disorder. Biovail will make tiered, royalty payments of 10% to 25% on net commercial sales of AZ-004. In addition to milestone payments and product royalties, Alexza will supply AZ-004 to BLS for all of its commercial sales, and will receive a per-unit transfer price, based upon annual product volume.
Conference Call Information Alexza will host a conference call Wednesday morning, February 10, 2010, at 8:30 a.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call and replay are open to all interested parties.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.
AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and submitted a New Drug Application submission in December 2009.
Alexza has completed an end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine) and has completed two Phase 2 studies with AZ-104 (Staccato loxapine, low-dose). Both product candidates are being developed for the acute treatment of migraine headache.
AZ-002 (Staccato alprazolam) has completed Phase 1 testing and one Phase 2a proof-of-concept clinical trial. Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releases from Alexza, is available online at www.alexza.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: ARGN - Amerigon Inc.)
LATEST NEWS!!
Amerigon Reports 2009 Fourth Quarter, Year-End Results
Record Quarterly Revenues; Profitable for the Year
NORTHVILLE, Mich., Feb 10, 2010 -- Amerigon Incorporated (Nasdaq: ARGN), a leader in developing and marketing products based on advanced thermoelectric (TE) technologies, today announced results for the fourth quarter and year ended December 31, 2009, which include record quarterly revenues of more than $21 million, higher gross margins and a profit for the full year.
Product revenues for the 2009 fourth quarter increased 68 percent to $21.6 million, compared with $12.8 million for the fourth quarter of 2008. Sequentially, this compares with $18.4 million for the 2009 third quarter. The increase in revenues was due to higher sales from new introductions of vehicles offering the Company's Climate Control Seat(R) (CCS(R)) systems and the addition of a rear seat option on certain existing vehicles subsequent to the 2008 fourth quarter. CCS systems include both TE-based heated and cooled systems and heated and ventilated seat systems. The increase was partially offset by lower volumes on existing vehicles.
Amerigon President and Chief Executive Officer Daniel R. Coker said, "I am very pleased to report that fourth quarter revenues reached record levels and we achieved profitability for the full year as net income for the quarter more than offset the loss in the first nine months of the year. The solid performance we experienced for the quarter is due primarily to the impact of new vehicles offering our seat systems. The popularity of our seat systems remains strong with both automotive manufacturers and consumers alike, and we are encouraged by the improvement of production levels at automotive manufacturers. We are also pleased with the early success we are seeing in our efforts to improve our gross margins. As we expected, the decrease in the cost of Tellurium, a key component of CCS, began to positively impact our gross margins during the quarter. Risks still exist beyond our control, but finding ways to improve our gross margins will continue to be an area of focus for us." Gross margin as a percentage of revenue for the 2009 fourth quarter was 29 percent compared with 22 percent in the 2008 fourth quarter. The year-over-year increase was primarily attributable to lower raw material costs, a favorable shift in the mix of products sold toward units having a higher gross margin percentage and higher coverage of fixed cost at the higher volume levels. Net income attributable to Amerigon Incorporated for the fourth quarter of 2009 was $1.4 million, or $0.07 per basic and $0.06 per diluted share, compared with net income attributable to Amerigon Incorporated in the 2008 fourth quarter of $291,000, or $0.01 per basic and diluted share.
For 2009, product revenues were $60.9 million, compared with $63.6 million for the prior year. Automotive production and sales volumes, impacted by slowing worldwide economic activity and the limited availability of consumer credit, were significantly lower during 2009, particularly in the first half of the year, as compared with the year earlier. In North America, one of the Company's most important markets, the Seasonally Adjusted Annual Rate ("SAAR") for vehicle sales decreased 21 percent to 10.4 million from 13.2 million during 2008. Vehicle production levels were decreased accordingly. During 2009, production of light vehicles in North America decreased by 32 percent to 8.6 million from 12.6 million during 2008.
Coker added, "We were able to maintain such strong revenue levels by introducing CCS on several new vehicle platforms that were launched during the year and increasing installation rates of CCS on existing light vehicle platforms. We expect that light vehicle production levels are likely to be higher during 2010." Gross margin as a percentage of revenue for 2009 was 26 percent compared with 29 percent in 2008. The year-over-year decrease was primarily attributable to higher raw material costs, an unfavorable shift in the mix of products sold toward units having a lower gross margin percentage and lower coverage of fixed cost at the lower volume levels. For 2009, net income attributable to Amerigon Incorporated was $723,000, or $0.03 per share, compared with net income attributable to Amerigon Incorporated of $3.6 million, or $0.16 per share, for 2008.
Amerigon completed its tenth full year of producing and selling CCS in 2009 and has shipped approximately 5.3 million units to-date.
Additional highlights of 2009 included the award of a contract to manufacture a heated and cooled cup holder that is expected to be launched in a full-size sedan by a major automotive manufacturer in the fall of 2010; the establishment of ZT Plus, a partnership with 5N Plus Inc; and the Company's BSST subsidiary being granted the fifth phase of the U.S. Department of Energy (DOE) program to install and test thermoelectric waste heat recovery systems on BMW Group and Ford vehicles.
Coker added that the Company is continuing its efforts to expand its applications of Amerigon's proprietary TE technology. Amerigon is pursuing heating and cooling applications in such markets as consumer goods, medical, computers, commercial heating and air conditioning and the military. The Company is also leading a team of high-profile commercial and academic partners studying the use of TE systems to convert waste heat from automobile exhaust into electric power.
"We are working on developing and commercializing products that will use advanced thermoelectric materials which will broaden and diversify our revenues in the years to come," Coker said.
The Company's balance sheet as of December 31, 2009 remained strong with cash, cash equivalents and short-term investments totaling $28.4 million, total assets of $62.4 million, no bank debt and shareholders' equity of $47.8 million.
CCS systems are currently offered as an optional or standard feature on 44 automobile models produced by Ford, General Motors, Toyota, Nissan, Hyundai and Tata Motors. New vehicles equipped with CCS systems and launched since the end of 2008 included the Lincoln MKT, Ford Taurus, Jaguar XK, Nissan 370Z Roadster, Infiniti G Convertible, KIA Mohave and KIA Borrego. Two existing programs, the Jaguar XJ and Land Rover Range Rover began offering CCS in the rear seating position for the first time during the 2009 third quarter.
Unit shipments of CCS systems for the 2009 fourth quarter and year were 309,000 and 874,000, respectively, compared with 188,000 and 931,000 units for the respective year-earlier periods.
The 2009 fourth quarter and full year results include year-over-year decreases in net research and development expenses of $370,000 and $789,000, respectively, due to the formation of ZT Plus, lower costs to support a smaller number of new vehicle programs launched during 2009 as compared to 2008 and lower costs associated with certain new product applications of the CCS technology that are currently in development.
Selling, general and administrative expenses for the 2009 fourth quarter and year increased $1.5 million and $1.7 million, respectively, due primarily to management bonuses, estimated future legal fees for a patent infringement lawsuit with competitor W.E.T. Automotive Systems, and higher stock option compensation expense as compared to 2008. The management incentive bonus program was cancelled during 2008 due to the significant economic and automotive downturn.
Guidance The Company expects product revenues in the 2010 first quarter to be up slightly compared with the 2009 fourth quarter, representing a more than 100 percent increase from the 2009 first quarter product revenue of $10.2 million. Although the automotive market appears to be beginning to stabilize, there continues to be significant market risk which makes it difficult for Amerigon to provide meaningful full-year 2010 guidance.
Conference Call As previously announced, Amerigon is conducting a conference call today to be broadcast live over the Internet at 11:30 AM Eastern Time to review these financial results. The dial-in number for the call is 1-877-941-1429. The live webcast and archived replay of the call can be accessed in the Events page of the Investor section of Amerigon's website at www.amerigon.com.
About Amerigon Amerigon (NASDAQ: ARGN) develops products based on its advanced, proprietary, efficient thermoelectric (TE) technologies for a wide range of global markets and heating and cooling applications. The Company's current principal product is its proprietary Climate Control Seat(R) (CCS(R)) system, a solid-state, TE-based system that permits drivers and passengers of vehicles to individually and actively control the heating and cooling of their respective seats to ensure maximum year-round comfort. CCS, which is the only system of its type on the market today, uses no CFCs or other environmentally sensitive coolants. Amerigon maintains sales and technical support centers in Southern California, Detroit, Japan, Germany, England and Korea.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockHunter.us
StockHunter.us is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockHunter.us. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2010 M2 COMMUNICATIONS
[ Back To Homepage ]
|
